Back to top

BioXcel Therapeutics regains compliance with Nasdaq

BioXcel Therapeutics (BTAI) announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market tha...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioXcel Therapeutics, Inc. (BTAI)